Stock Events

Stock Events

Disc Medicine 

$78.02
22
-$1.35-1.7% 12:44 Today

Statistics

Day High
79.45
Day Low
79.28
52W High
99.5
52W Low
40
Volume
41,271
Avg. Volume
-
Mkt Cap
3.05B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.77
-1.5
-1.22
-0.95
Expected EPS
-1.677442
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-212.18MNet Income

Analyst Ratings

101.67Average Price Target
The highest estimate is 120.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IRON. It's not an investment recommendation.
Amazon
4
AMZN
NVIDIA
3
NVDA
Meta Platforms
3
META
MARA
3
MARA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Disc Medicine's treatments for blood disorders.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals develops treatments for cystic fibrosis and other serious diseases, including blood disorders, potentially competing with Disc Medicine.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a broad portfolio including treatments for HIV, liver diseases, and hematology, directly competing with Disc Medicine's focus.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including treatments for blood disorders, making it a competitor.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals develops medicines for serious medical conditions, including hematologic conditions, competing with Disc Medicine.
Novartis
NVS
Mkt Cap292.35B
Novartis offers a wide range of healthcare solutions, including treatments for blood disorders, directly competing with Disc Medicine.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on rare genetic diseases, some of which involve hematologic disorders, making it a competitor.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals is pioneering RNA interference (RNAi) therapeutics, which could target similar diseases as Disc Medicine.

About

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Show more...
CEO
John D. Quisel
Employees
165
Country
United States
ISIN
US2546041011

Listings

BOATS
BOATS
IRON.BOATS
XNAS
US
IRON

0 Comments

Share your thoughts

FAQ

What is Disc Medicine stock price today?▼
The current price of IRON is $78.02 USD — it has decreased by -1.7% in the past 24 hours. Watch Disc Medicine stock price performance more closely on the chart.
What is Disc Medicine stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Disc Medicine stocks are traded under the ticker IRON.
Is Disc Medicine stock price growing?▼
IRON stock has fallen by -0.82% compared to the previous week, the month change is a +2.02% rise, over the last year Disc Medicine has showed a +31.87% increase.
What is Disc Medicine market cap?▼
Today Disc Medicine has the market capitalization of 3.05B
When is the next Disc Medicine earnings date?▼
Disc Medicine is going to release the next earnings report on November 05, 2026.
What were Disc Medicine earnings last quarter?▼
IRON earnings for the last quarter are -1.54 USD per share, whereas the estimation was -1.71 USD resulting in a +10.08% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Disc Medicine revenue for the last year?▼
Disc Medicine revenue for the last year amounts to 0 USD.
What is Disc Medicine net income for the last year?▼
IRON net income for the last year is -212.18M USD.
How many employees does Disc Medicine have?▼
As of September 04, 2026, the company has 165 employees.
In which sector is Disc Medicine located?▼
Disc Medicine operates in the Health & Wellness sector.
When did Disc Medicine complete a stock split?▼
Disc Medicine has not had any recent stock splits.
Where is Disc Medicine headquartered?▼
Disc Medicine is headquartered in WATERTOWN, United States.